Buchumschlag

Precision medicine approach to detect obese people who are at high risk of developing diabetes

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
1. Verfasser:	Iskandar Idris
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Diabetes, Obesity and Metabolism Now
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Glucagon like peptide‐1 (GLP‐1) therapy is associated with reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes with chronic liver disease
von: Iskandar Idris
Veröffentlicht: (2024)

Adults who are overweight or obese may experience greater pain intensity compared with normal weight individuals?
von: Iskandar Idris
Veröffentlicht: (2024)

Appropriate timing of exercise for adults with obesity including those with type 2 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Can diet and exercise intervention prevent type 2 diabetes in individuals with a high genetic risk?
von: Iskandar Idris
Veröffentlicht: (2024)

Tirzepatide shown to improve clinical outcomes for patients with heart failure with preserved ejection fraction (HFpEF) and obesity
von: Iskandar Idris
Veröffentlicht: (2024)

Fenofibrate shown to reduce progression of diabetic retinopathy
von: Iskandar Idris
Veröffentlicht: (2024)

Epigenetic changes shown to cause type 2 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Hybrid closed‐loop therapy significantly improved maternal glucose control during pregnancy complicated by type 1 diabetes
von: Iskandar Idris
Veröffentlicht: (2024)

Potential role of glucagon like peptide (GLP)‐1 receptor agonist to reduce risk of colorectal cancer?
von: Iskandar Idris
Veröffentlicht: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
von: Iskandar Idris
Veröffentlicht: (2024)

Extension study from DIRECT showed ongoing remission rate from type 2 diabetes in some patient following very low calorie diet at 5 years
von: Iskandar Idris
Veröffentlicht: (2024)

The glucagon like peptide‐1 linked to nonarteritic anterior ischemic optic neuropathy
von: Iskandar Idris
Veröffentlicht: (2024)

Tirzepatide shown to be effective at reducing sleep disturbances in patients with obstructive sleep apnoea
von: Iskandar Idris
Veröffentlicht: (2024)

The US Food and Drug administration has approved resmetirom as the first drug to treat metabolic dysfunction‐associated steatohepatitis (MASH)
von: Iskandar Idris
Veröffentlicht: (2024)

Potential new therapies to preserve lean muscle mass loss when used in combination with glucagon‐like peptide 1 (GLP‐1) receptor agonist being studied
von: Iskandar Idris
Veröffentlicht: (2024)

Real world data showed that the dual GLP gip agonist, Tirzepatide is associated with lower mortality, cardiovascular events and adverse kidney events compared with GLP‐1 analogue
von: Iskandar Idris
Veröffentlicht: (2024)

Increased expression of the protein Kallistatin after weight loss induces beneficial metabolic effects: A potential new therapeutic target?
von: Iskandar Idris
Veröffentlicht: (2024)

Increasing excess to weight loss injection shown to save thousands of lives a year
von: Iskandar Idris
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

Issue Information
Veröffentlicht: (2024)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
von: Iskandar Idris, et al.
Veröffentlicht: (2025)

Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
von: Scott A. Coon, et al.
Veröffentlicht: (2025)

Interventions to improve glycaemic control in people living with, and at risk of developing type 2 diabetes
von: Nerys M. Astbury
Veröffentlicht: (2024)

Overweight or obesity, weight variability and the risk of retinopathy in type 1 diabetes
von: Thomas Nyström, et al.
Veröffentlicht: (2024)

Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
von: Testimony Ipaye, et al.
Veröffentlicht: (2025)

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial
von: Lin Zhao, et al.
Veröffentlicht: (2025)

Accelerated onset of diabetes in non‐obese diabetic mice fed a refined high‐fat diet
von: Heidi M. Batdorf, et al.
Veröffentlicht: (2024)

Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial
von: Joanna Y. Gong, et al.
Veröffentlicht: (2025)

Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis
von: Leonardo A. Mesquita, et al.
Veröffentlicht: (2024)

Impact of bariatric surgery on glycaemic and metabolic outcomes in people with obesity and type 2 diabetes mellitus: A meta‐analysis
von: Xu Han, et al.
Veröffentlicht: (2025)

The melanocortin‐4 receptor pathway and the emergence of precision medicine in obesity management
von: Sima Fansa, et al.
Veröffentlicht: (2024)

Perceptions, attitudes and barriers to effective obesity care among people with obesity and health care professionals in India
von: A. G. Unnikrishnan, et al.
Veröffentlicht: (2024)

Changes in thyroid hormones predict weight regain in patients with obesity who undergo metabolic surgery
von: Yi Tang, et al.
Veröffentlicht: (2024)

Sodium‐glucose co‐transporter 2 inhibitors and obesity‐associated cancers in people with type 2 diabetes: A real‐world observational study
von: Testimony Ipaye, et al.
Veröffentlicht: (2026)